The Impact of PBMs on Medicare and Medicaid: A Study Overview
Discover how PBMs influence Medicare and Medicaid markets, focusing on drug prices, regulation, and accountability in healthcare practices.
New Federal Reforms on Pharmacy Benefit Managers Impact Health Plans
Discover how the new federal reforms on pharmacy benefit managers are reshaping health plans and Medicare Part D with a focus on transparency and compliance.
Healthcare Cost Changes in 2026: Implications for the Insurance Industry
Explore how the 2026 healthcare cost changes will impact insurance, with strategic insights on Medicare, ACA, and new drug pricing structures.
CMS Updates on Medicare Drug Price Negotiation and 340B Rebate Litigation
CMS announces changes to Medicare drug price negotiations; ongoing litigation surrounds 340B rebate model and state drug pricing laws, affecting Medicare Advantage plans and Part D reimbursement.
House GOP Proposes Employer Insurance Expansion, PBM Controls as ACA Subsidies Expire
With enhanced ACA subsidies expiring, House Republicans propose expanding employer insurance access and regulating PBMs to address drug costs, while bipartisan efforts seek subsidy extensions.
Medicare Drug Price Negotiations Yield Significant Savings for 15 Key Medications
Pharmaceutical companies agree to reduce Medicare prices for 15 prescription drugs, potentially saving billions in taxpayer and patient costs under new negotiation rules starting in 2027.
China Launches Commercial Health Insurance List Featuring CAR-T Therapies
China launches its first Commercial Health Insurance Innovative Drug List with CAR-T therapies, advancing access to innovative cancer and rare disease treatments under commercial insurance.
CMS Negotiates Discounts on 15 Drugs, Including Cancer Therapies
CMS has secured significant price reductions on 15 drugs including costly cancer treatments, impacting Medicare Part B pricing and healthcare costs.
CMS Expands Medicare Drug Price Negotiations to 25 Medications
CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.
CMS Announces 2027 Medicare Part D Drug Price Reductions for 15 High-Cost Medications
CMS reveals new 2027 price caps for 15 Medicare Part D drugs, projected to save billions federally and reduce patient costs under the Inflation Reduction Act negotiations.